Tella And Waseda University Start Immunotherapy Combo Study For Pancreatic Cancer
This article was originally published in PharmAsia News
Executive Summary
JASDAQ-listed biotech venture firm Tella And Waseda University started a clinical study combining immunotherapy with cancer drugs on patients with pancreatic cancer